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Mercury is a toxic heavy metal occurring
in several physical and chemical forms.
Elemental mercury (Hg0) emitted to the
atmosphere is converted to soluble forms,
deposited into soil and water, and methylated
to methylmercury (MeHg). Fish and dental
amalgam are two major sources of human
exposure to organic (MeHg) and inorganic
Hg, respectively. The exposure from dental
amalgam occurs mainly by inhalation of Hg0
evaporating from the fillings [World Health
Organization (WHO) 1991]. 
The central nervous system and the kidney
are the primary target organs for mercury toxi-
city (Agency for Toxic Substances and Disease
Registry 1999; Clarkson and Magos 2006;
WHO 2003). The exposure and body burden
of mercury can be estimated by monitoring of
mercury in hair (organic Hg), blood (both
organic and inorganic Hg), and urine (mainly
inorganic Hg). For inorganic Hg, the urinary
mercury level (U-Hg) is widely used for
screening (Barregard 1993). It is inﬂuenced by
the mercury concentration in the kidneys,
which is higher than in most other organs. 
An early effect of mercury vapor exposure
is the effect on the renal proximal tubules.
Low-molecular-weight proteins such as alpha-
1-microglobulin (A1M) are reabsorbed slightly
less effectively, and lysosomal enzymes, such as
N-acetyl-β-D-glucosaminidase (NAG), are
excreted in increased amounts. Enzymuria has
been reported at occupational exposure to
U-Hg of about 10–20 µg/g creatinine
(Ellingsen et al. 2000). In children, however, a
recent European study showed a positive asso-
ciation between U-Hg and urinary NAG at
very low levels (< 1 µg/g creatinine) of U-Hg
(de Burbure et al. 2006). Renal effects of toxic
heavy metals have also be shown on brush-
border enzymes, like γ-glutamyl transpeptidase
(γ-GT) (Gotelli et al. 1985). 
High occupational mercury exposure has
been shown to increase the excretion of albu-
min, but mainly at U-Hg levels ≥ 100 µg/g
creatinine. At lower exposure levels, albumin
excretion has generally not been increased
(Barregard et al. 1997; Buchet et al. 1980;
Roels et al. 1985). In rare cases, high mercury
exposure may cause immune-complex medi-
ated glomerulonephritis and nephrotic syn-
drome (Enestrom and Hultman 1995; Tubbs
et al. 1982), and animal models have been
developed for mercury-induced autoimmunity
(Nielsen and Hultman 2002; Pollard et al.
2005). In children too, renal effects of mer-
cury exposure occur (Counter and Buchanan
2004). In addition a condition called acrody-
nia, or “pink disease,” including systemic
symptoms and signs and skin rash, has been
reported with inorganic mercury exposure
(Dye et al. 2005; Weinstein and Bernstein
2003). This syndrome may include hyper-
sensitivity to mercury because not all children
with the same exposure were affected. 
Typical U-Hg levels in adults with amal-
gam fillings are much lower than in those
where renal effects have been shown—for
example, a mean of 1.1 µg/g creatinine in a
representative sample of 1,600 U.S. women
16–49 years of age in the NHANES
(National Health and Nutrition Examination
Study) study (Dye et al. 2005), and 1.9 µg/g
creatinine in 1,100 healthy male U.S. veterans
(mean age, 53 years) (Kingman et al. 1998).
Similar levels are found in Canada and
Central or Northern Europe (Barregard et al.
2006; Becker et al. 2003; Factor-Litvak et al.
2003). The distribution is log-normal, and
U-Hg of 10–25 µg/g creatinine is found in a
small fraction of the general population in the
United States and Europe, for example,
among heavy chewing-gum users with amal-
gam fillings (Barregard et al. 1995; Sallsten
et al. 1996). We found no population-based
study on U-Hg in U.S. children. In central
Europe, however, levels are typically around
0.5 µg/g creatinine, with higher levels
(1–2 µg/g creatinine) in the Mediterranean
areas and coastal Canada. Dental amalgam
and ﬁsh consumption are the main sources of
variability (Batariova et al. 2006; de Burbure
et al. 2006; Evens et al. 2001; Levy et al.
2004; Pesch et al. 2002; Trepka et al. 1997;
Wilhelm et al. 2006). No systematic reviews
or meta-analyses have been performed on the
safety of dental amalgam. 
We report here the results on markers of
possible effects on the kidneys in the New
England Children’s Amalgam Trial (NECAT),
one of two randomized clinical trials com-
paring the health of children whose caries
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(A1M), γ-glutamyl transpeptidase (γ-GT), and N-acetyl-β-D-glucosaminidase (NAG). These mark-
ers were measured on several occasions during the trial, together with urinary mercury and covari-
ates. We evaluated the results using repeated-measures analyses. 
RESULTS: There were no signiﬁcant differences between treatment groups in average levels of renal
biomarkers, nor signiﬁcant effects of number of dental amalgams on these markers. There was, how-
ever, a signiﬁcantly increased prevalence of microalbuminuria (MA) among children in the amalgam
group in years 3–5 (adjusted odds ratio 1.8; 95% conﬁdence interval, 1.1–2.9). Most of these cases
are likely to be temporary MA, but 10 children in the amalgam group had MA in both years 3 and 5,
versus 2 children in the composite group (p = 0.04). There were no differences in the occurrence of
high levels of renal tubular markers (A1M, γ-GT, or NAG).
CONCLUSIONS: The increase in MA may be a random finding, but should be tested further. The
results did not support recent ﬁndings in an observational study of an effect of low-level mercury on
tubular biomarkers in children. 
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23 November 2007]were restored using either dental amalgam or
alternative materials. The first report from
NECAT focused on the primary end points
of neuropsychological performance. For renal
markers, only an overall comparison of albu-
min levels in the two treatment groups was
reported (Bellinger et al. 2006). No adverse
neuropsycological effects of dental amalgam
were found in either trial (Bellinger et al.
2006; DeRouen et al. 2006). 
Participants and Methods
A detailed description of the design of the
NECAT study has been presented elsewhere
(Children’s Amalgam Trial 2003), as well
as details on follow-up per CONSORT
(Consolidated Standards of Reporting Trials)
guidelines, dental treatment, and mercury
exposure (Bellinger et al. 2006). Approvals
were obtained from the relevant institutional
review boards. 
In summary, children 6–10 years of age,
with no prior or existing amalgam restorations
but with two or more occlusal dental caries
lesions were recruited over a 2-year period in
Boston, Massachusetts, and Farmington,
Maine. Baseline visits included a dental exami-
nation, blood and urine samples, anthropo-
metric measurements, health interviews, and
neuropsychological testing of the child.
Exclusion criteria were clinical evidence of
existing psychological, behavioral, neurologic,
immunosuppressive, or renal disorders.
Eligibility was confirmed for 598 children,
and parental consent and child assent obtained
for 534. These children were randomized to a
study treatment group, stratified by geo-
graphic location (Boston vs. Farmington) and
number of teeth with caries (2–4 vs. ≥ 5).
Power calculations were based not on renal
markers but on potential changes in IQ score.
Post hoc power calculations (based on log-
transformed levels) show, however, that our
study had adequate power to detect an
increase of NAG in the amalgam group of the
size reported by de Burbure et al. (2006). For
NAG and albumin we had 80% power (α =
0.05) to detect an increase in geometric means
of about 20% in the amalgam group. 
Interventions and follow-up. A dispersed
phase amalgam or a resin composite material
(white ﬁlling) was used to restore all posterior
teeth with caries at baseline and incident
caries during the 5-year trial period, accord-
ing to treatment group (Bellinger et al.
2006). Following standard clinical practice,
however, for both groups, composite material
was used to restore caries in the front teeth.
Participants and dentists could not be
blinded to treatment assignment, but all who
collected outcome data (including interview-
ers) or who analyzed specimens at core labo-
ratories were blinded to children’s treatment
assignments. 
Children in both groups had semiannual
dental examinations. At the annual visits, neuro-
psychological testing and anthropometric mea-
surements were performed and a urine sample
collected (Bellinger et al. 2006). We initially
attempted to collect timed overnight urine sam-
ples, but switched to spot samples mid-trial. 
Dental amalgam and mercury exposure.
The number of dental restorations was high-
est early in the trial because of unmet treat-
ment needs. At baseline, children had an
average of 9.5 decayed tooth surfaces (range,
2–39). In subsequent years the children had
on average approximately one new surface
filled per year, while decidual teeth (some
with fillings) were shed. In year 5, the chil-
dren had 0–36 surfaces ﬁlled, with a median
of four surfaces (three amalgam) in the amal-
gam group and ﬁve in the composite group. 
The key measure of mercury burden was
mercury in urine, corrected for creatinine
(U-Hg in micrograms per gram creatinine),
details on the analysis as reported by
Bellinger et al. (2006). The detection limit,
initially 1.5 µg/L, was reduced to 0.45 µg/L
after 1 February 2000 as a result of increasing
the volume of urine analyzed from each
child. Nondetectable concentrations (< 0.45
µg/L) were imputed as 0.45/   2 (Hornung
and Reed 1990). The mercury concentra-
tions in the two treatment groups are shown
in Figure 1. Also hair mercury levels and
blood lead were measured (Bellinger et al.
2006), because methylmercury and lead
could affect neuropsychological performance
and kidney function. 
Renal markers. At baseline and in annual
follow-up, we determined the level of γ-GT as
well as a dip-stick test of proteinuria. At years
3 and 5, we added the assays of albumin,
A1M, and NAG, to further assess possible
mild renal effects. 
γ-GT was measured in the Clinical
Laboratory of the Rochester General Hospital
(Rochester, NY, USA) using the Dimension
system GGT Flex reagent cartridge from
Dade Behring. Urinary albumin, A1M, and
NAG were determined at the Sahlgrenska
University Hospital. Albumin was deter-
mined by an automated nephelometric
immunochemical method using reagents and
calibrator from Beckman Coulter (Fullerton,
CA, USA). Additional internal reference sam-
ples were used in each analytical run. The
detection limit was 2.4 mg/L. The excretion
of albumin was expressed in milligrams per
gram creatinine. 
Excretion of albumin > 30 mg/g creati-
nine was considered microalbuminuria (MA)
(American Diabetes Association 2004). If a
urine sample showed increased urinary albu-
min, the parents/caregivers were recom-
mended to contact their pediatrician (or ask
the NECAT trial group for help in locating a
nearby clinic). While the trial was ongoing,
the families were also given the option of pro-
viding a new urine sample which was reana-
lyzed for albumin. The criterion for taking
this action was albumin > 4 mg/mmol creati-
nine (35 mg/g creatinine) and albumin con-
centration > 20 mg/L. 
We determined the level of A1M by auto-
mated nephelometric immunochemical meth-
ods using reagents and calibrator from
Beckman Coulter. Additional internal reference
samples were used in each analytical run. The
detection limit was 4 mg/L for A1M. To com-
pare our A1M levels with most previous studies
reported using antibodies from Dako (Jarup
et al. 2000), we divided our A1M concentra-
tions by 1.4 because we found that the concen-
trations in the two commercial antigens
(calibrators) differed, with 40% higher levels
using the Beckman Coulter reagents. Because
only about 30% of the urine samples (with sim-
ilar numbers in each treatment group) had
detectable levels of A1M, we reanalyzed (2 years
later) those urine samples from year 5 with suf-
ficient volume still remaining after previous
analyses, using a commercial ELISA kit for
A1M from Immundiagnostik AG (Bensheim,
Germany; detection limit 0.1 mg/L). 
We determined total NAG with an
automated photometric method based on
the formation of 3-cresol purple at the reac-
tion catalysed by NAG, using reagents and
calibrator from Roche Diagnostics (Basel,
Switzerland) (detection limit 0.1 U/L), and
expressed in units per gram creatinine. Urinary
creatinine was determined at the Swedish and
the Rochester laboratories by the photometric
Jaffe method (detection limit 0.1 g/L). 
Urine samples were stored frozen at
–20°C until analysis with median storage
times of 2 months for γ-GT, 6 months for
albumin and NAG, 9 months for A1M with
nephelometry, and 31 months for A1M using
ELISA. Owing to the range of storage times,
data analysis controlled for storage time. 
Renal effects of dental amalgam in children
Environmental Health Perspectives • VOLUME 116 | NUMBER 3 | March 2008 395
Figure 1. Distribution of U-Hg in children treated
with amalgam or composite dental ﬁllings in years
3–5 of the 5-year New England Children’s Amalgam
Trial. The boxplots show the median (middle line),
25th and 75th percentiles (box), the extreme values
(whiskers of 1.5 times the interquartile range), and
the outliers (highest values).
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)Twelve percent of albumin and 6% of
NAG concentrations were below the level of
detection, with similar numbers in each treat-
ment group. These nondetectable concentra-
tions were imputed as detection limit/   2
for analysis. For A1M using nephelometry,
nondetectable A1M levels were imputed as
detection limit/2 for descriptive purposes only
(Hornung and Reed 1990).
Data analyses. For the assessment of possi-
ble effects on renal markers, we excluded six
children with diabetes (one at baseline, five
during follow-up; three in each treatment
group), and six with other kidney disease (all
postbaseline; three in each treatment group), as
reported by parents in annual health inter-
views. In addition, we excluded children with
increased excretion of γ-GT at baseline (seven
in the amalgam group and 17 in the composite
group), because they may have had a disease
affecting kidney function already before dental
treatment. The cutoff for γ-GT was the 95th
percentile for all children at baseline (66 U/g
creatinine). At each visit, there were some chil-
dren who did not supply a urine sample.
Additionally, some of the samples were too
small to permit several analyses, so priority was
given to the mercury and γ-GT analyses at the
laboratory in Rochester. Consequently, the
total numbers of results are lower for albumin,
A1M, and NAG. Furthermore, sample sizes
are lower in year 2 because of funding uncer-
tainty and severe curtailment of data collection.
Data analyses were performed based on
renal markers as continuous as well as cate-
gorical variables, the latter based on the num-
ber of high values above certain cutoff limits.
For albumin we used 30 mg/g creatinine as
the cutoff for MA (American Diabetes
Association 2004). For urinary A1M, NAG,
and γ-GT, there are no general reference lim-
its in children. Therefore, we used the 95th
percentiles in the composite group for years
1–5 (γ-GT), year 5 (A1M with ELISA), or
years 3–5 (the other markers). When the
renal markers were analyzed as continuous
variables, levels were log-transformed. 
Three outcome times were considered:
a) year 1 for γ-GT (ﬁrst visit after placement of
dental fillings), b) years 3–5 for all markers
except A1M with ELISA, and c) year 5 (end of
the trial) for all markers. Furthermore, three
predictors were used for each outcome: treat-
ment group, number of amalgam and compos-
ite ﬁllings (two separate variables), and U-Hg
level (years 3–5 only, because a less sensitive
limit of detection was used earlier in the trial).
We performed analysis of covariance
(ANCOVA) (for the continuous outcomes)
and logistic regression (for the categorial out-
comes) for all three predictors. We used
repeated-measures models with compound
symmetric variance structure for the outcomes
over years 3–5. All models controlled for ran-
domization stratum, age, sex, race (non-
Hispanic white, non-Hispanic black, Hispanic,
other), socioeconomic status (Green 1970),
baseline hair mercury level, baseline blood
lead level (BPb), lean body mass, type of spec-
imen (overnight vs. spot daytime urine sam-
ple), urinary creatinine concentration (as a
surrogate for urinary ﬂow rate), storage time,
and baseline γ-GT (for γ-GT models only). In
the models with U-Hg as predictor, we also
tested a term for an interaction between BPb
and U-Hg. 
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Table 2. Summary of the results for renal markers at baseline and follow-up in 490a children [median (no.)
and range].
Baseline Year 1 Year 2 Year 3 Year 4 Year 5b
γ-GT (U/g creatinine)
Amalgam group 19.5 (238) 19.4 (186) 26.4 (126) 31.9 (185) 36.5 (192) 39.3 (204)
2.1–66  1.5–73  < 1–73 1.1–100 < 1–146 3.6–125
Composite group 17.4 (223) 19.7 (182) 24.5 (139) 34.5 (180) 36.9 (173) 40.2 (198)
2.0–62 1.0–89 < 1–124 0.9–247 1.5–132 2.6–143
Albuminc (mg/g creatinine)
Amalgam group 6.8 (135) 6.0 (193)
< DL–773 < DL–771
Composite group 7.9 (148) 6.5 (186)
< DL–208 < DL–687
NAGc (U/g creatinine)
Amalgam group  1.4 (135) 1.2 (193)
< DL–4.7 < DL–3.7
Composite group 1.4 (148) 1.2 (186)
< DL–4.8 < DL–7.8
A1Mc (mg/g creatinine)
Amalgam group  < DL (135) < DL (193)d
< DL–29 < DL–29
Composite group < DL (148) < DL (186)d
< DL–21 < DL–29
DL, detection limit. 
aOf the 534 children, 36 were excluded from analysis because of parent-reported diabetes (n = 6), other renal disease (n =
6), or high baseline γ-GT (n = 24). An additional 8 children never provided urine samples throughout the trial. bIn ANCOVA
models for treatment group, controlling for randomization stratum, age, sex, race, socioeconomic status, baseline hair
mercury, baseline BPb, lean body mass, time of specimen (overnight vs. daytime), creatinine concentration, storage time,
and baseline γ-GT (for γ-GT models only), p = 0.86 for γ-GT, p = 0.46 for albumin, p = 0.95 for NAG, and p = 0.79 for A1M.
cSamples below the detectable concentration were imputed as detection limit/   2 (for albumin and NAG) or detection
limit/2 (for A1M) for computation of the medians and maximums. dReanalysis of A1M from year 5 using ELISA showed a
median A1M of 0.66 (range, 0.06–5.0) mg/g creatinine (n = 90) in the amalgam group and 0.55 (range, 0.07–7.4) mg/g creati-
nine (n = 97) in the composite group, p = 0.80.
Table 1. Baseline characteristics of NECAT participants (n = 534a).
Characteristic Amalgam group (n = 267) Composite group (n = 267)
Site [n (%)]
Boston, Massachusetts 144 (53.9) 147 (55.1)
Farmington, Maine 123 (46.1) 120 (44.9)
No. of carious surfaces [mean ± SD (range)] 9.8 ± 6.9 (2–39) 9.3 ± 6.2 (2–36)
Age [mean ± SD (range)] 7.9 ± 1.3 (5.9–11.4) 7.9 ± 1.4 (5.9–11.5)
Sex [n (%)]
Female 131 (49.1) 156 (58.4)
Male 136 (50.9) 111 (41.6)
Race [n (%)]b
Non-Hispanic white 165 (64.0) 158 (60.3)
Non-Hispanic black 49 (19.0) 49 (18.7)
Hispanic 15 (5.8) 23 (8.8)
Other 29 (11.2) 32 (12.2)
Household income [n (%)]
≤ $20,000 74 (29.2) 86 (33.1)
$20,001–$40,000 113 (44.7) 109 (41.9)
> $40,000 66 (26.1) 65 (25.0)
Education of primary caretaker [n (%)]
< High school 34 (13.2) 38 (14.6)
High school graduate 197 (76.4) 194 (74.3)
College graduate 18 (7.9) 17 (6.5)
Postcollege degree 9 (3.5) 12 (4.6)
Hair mercury [µg/g (mean ± SD)] 0.4 ± 0.5 0.4 ± 0.5
BPb [µg/dL (mean ± SD)]  2.4 ± 1.9 2.3 ± 1.5
aThe number of trial participants includes those who later withdrew (85 of 534, 42 in the amalgam group and 43 in the
composite group). For race, data were available for 520 participants; for income, 513; for education, 519. bRace was self-
reported by the parents of the children. The other category included individuals who identified themselves as Asian,
Paciﬁc Islander, Native American, biracial, or other, which they were asked to specify.Results
Children in the two treatment groups were
similar in terms of most baseline characteris-
tics (Table 1). The numbers of girls and boys
were comparable in the amalgam group, but
girls outnumbered boys in the composite
group. Participants were primarily non-
Hispanic white (62%), with non-Hispanic
blacks comprising 19% of the sample.
Baseline hair mercury and BPb were similar. 
The distributions for renal markers strati-
ﬁed by year and treatment group are shown in
Table 2. The differences were small and none
of them statistically signiﬁcant for γ-GT, albu-
min, or NAG (p > 0.3 for ANCOVA models).
Figure 2 shows median γ-GT, albumin, and
NAG stratiﬁed by number of amalgam ﬁllings
at year 5. There were no signiﬁcant effects of
number of fillings, nor U-Hg level in
ANCOVA models (p > 0.2 for all), except for
a decrease of γ-GT in years 3–5 with increas-
ing number of composite fillings. Models
including also an interaction between BPb and
U-Hg showed no such interaction for γ-GT or
NAG. In the model for albumin, the interac-
tion term U-Hg*BPb was positive and statisti-
cally signiﬁcant (p = 0.04 for year 3–5 and p =
0.008 for year 5). The model indicated a 34%
increase of urinary albumin at U-Hg 1.5 µg/g
creatinine and BPb 4 µg/dL (90th percentiles)
compared with children with median U-Hg
and BPb levels (0.52 µg/g creatinine and 2
µg/dL) in year 5. For A1M, only 29% of the
samples were above the detection limit (29%
and 30% in the amalgam and composite
groups, respectively) using nephelometry,
making a treatment group comparison mean-
ingless. With the ELISA method, the low con-
centrations could be quantiﬁed, but the levels
had now decreased substantially after more
than two years of storage. However, no signiﬁ-
cant treatment group difference was observed
(p > 0.4 for all models).
In Table 3 we present the number of high
values by treatment group and year. The over-
all differences between groups were not statis-
tically signiﬁcant for γ-GT, NAG, or A1M in
logistic regression models. Exposure–response
analyses also showed no effects of number of
ﬁllings or U-Hg level on these markers except
a moderately signiﬁcant decrease in the preva-
lence of high γ-GT with increasing numbers
of both amalgam and composite ﬁllings (p =
0.02 and 0.03, respectively). 
However, the prevalence of urinary albu-
min > 30 mg/g creatinine (here called MA
even if some of them had albuminuria) in
year 3 or year 5 was higher in the amalgam
group than in the composite group [repeated-
measures logistic regression: odds ratio (OR)
= 1.8; 95% conﬁdence interval (CI), 1.1–2.9;
p = 0.03]. The tendency was similar in year 3
and year 5 (OR = 1.8 in both cases). Crude
ORs were slightly lower than those in the
adjusted models (e.g., OR = 1.6; 95% CI,
0.98–2.5; p = 0.06) for MA in year 3–5.
There was no signiﬁcant increase in MA with
increasing numbers of amalgam fillings (p =
0.30) or U-Hg excretion (p = 0.71). However,
when an interaction term BPb*U-Hg was
included in the model with U-Hg as predictor,
it was statistically signiﬁcant in year 5 (p = 0.02)
and nearly so in years 3–5 (p = 0.07). 
There were 48 occasions of MA in 38
children in the amalgam group at the 3-year
and/or 5-year visits, versus 33 occasions in 31
children in the composite group. Ten chil-
dren in the amalgam group (0–12 amalgam
surfaces; median, 3) had MA on both visits,
but only two in the composite group (p =
0.04; Fisher’s exact test). There was no signif-
icant interaction between treatment group
and sex (p = 0.27). Therefore, the fact that the
OR for MA was significantly increased only
in boys should be considered hypothesis gen-
erating only. When urine samples with albu-
min > 30 mg/g creatinine but < 20 mg/L and
creatinine < 0.3 g/L (i.e., samples with rela-
tively low creatinine where the classification
of MA could be considered less clear) were
excluded, the results were similar (34 children
with MA in the amalgam group and 9 of
them on both visits, vs. 28 in the composites
group and 1 of them on both visits). Twelve
of the children had urinary albumin > 200
mg/g creatinine (two in year 3 only, nine in
year 5 only, and one at both visits). Eight of
them belonged to the amalgam group
Renal effects of dental amalgam in children
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Figure 2. Urinary excretion of (A) γ-GT, (B) albumin, and (C) NAG by number of amalgam ﬁllings in year 5 of the New England Children’s Amalgam Trial. Sample
sizes are slightly higher for γ-GT because priority was given to this assay. Samples of sufﬁcient volume were also analyzed for albumin and NAG. Numbers above
the bars are percentages of (A) high γ-GT, (B) MA, and (C) high NAG.
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Table 3. Prevalence of high valuesa for renal markers at follow-up in 458 children [no./total sample (%)].b
Year 1 Year 2 Year 3 Year 4 Year 5c
γ-GT (U/g creatinine)
Amalgam group 2/186 (1.1) 1/126 (0.8) 13/185 (7.0) 16/192 (8.3) 20/204 (9.8)
Composite group 2/182 (1.1) 6/139 (4.3) 13/180 (7.2) 13/173 (7.5) 20/198 (10)
Albumind (mg/g creatinine)
Amalgam group  18/135 (13) 30/193 (16)
Composite group 15/148 (9.5) 18/186 (9.7)
NAGd (U/g creatinine)
Amalgam group  5/135 (3.7) 5/193 (2.6)
Composite group 8/148 (5.4) 8/186 (4.3)
A1Md (mg/g creatinine)
Amalgam group  5/135 (3.7) 5/193 (2.6)e
Composite group 13/148 (8.8) 3/186 (1.6)e
aCutoffs were 71.9 U/g creatinine for γ-GT, 30 mg/g creatinine for albumin, 3.1 U/g creatinine for NAG, 10.5 mg/g creatinine
for A1M (nephelometry), and 3.7 mg/g creatinine for A1M (ELISA). These were chosen as the 95th percentile of the com-
posite group, except for albumin, which uses a standard cutoff. bOf the 534 children, 36 were excluded from analysis
because of parent-reported diabetes (n = 6), other renal disease (n = 6) or high baseline γ-GT (n = 24). Eight children never
provided urine samples, and an additional 32 children never provided samples after baseline. cIn logistic regression mod-
els for treatment group, controlling for randomization stratum, age, sex, race, socioeconomic status, baseline hair mer-
cury, baseline BPb, lean body mass, time of specimen (overnight vs. daytime), creatinine concentration, storage time, and
baseline γ-GT (for γ-GT models only), p = 0.85 for γ-GT, p = 0.07 for albumin, p = 0.59 for NAG, and p = 0.89 for A1M.
dSamples below the detectable concentration were imputed as detection limit/   2 (for albumin and NAG) or detection
limit/2 (for A1M). eReanalysis of A1M from year 5 using ELISA showed 1/90 (1.1%) and 4/97 (4.1%) high A1M in the amal-
gam and composite groups, respectively, p = 0.11.(including the one at both visits) and four to
the composite group.
The exclusion of children with diabetes,
kidney disease, or high γ-GT at baseline was
done a priori, without knowledge of their
albumin levels. Nevertheless, in view of the
results reported above, we examined also the
albumin excretion of these children. As could
be expected, MA was more common in these
children; in 36 children excluded a priori,
albumin excretion was measured in 32 chil-
dren, and 7 of them had MA in year 3 and/or
year 5. 
Discussion 
In adults, an early effect of inorganic mercury
is on the renal proximal tubules. In the pre-
sent study we found no indications of tubular
toxicity. We used three different tubular bio-
markers; a brush border enzyme (γ-GT), a
lysosomal enzyme (NAG), and a low-molecu-
lar-weight protein (A1M). NAG is a com-
monly used biomarker in studies of tubular
effects of inorganic mercury (Ellingsen et al.
2000). A recent cross-sectional study in
European children found, surprisingly, a posi-
tive association between the excretion of
NAG and mercury at U-Hg levels as low as in
the present study (de Burbure et al. 2006).
The long-term clinical significance of
increased levels of NAG and A1M is unclear,
but these two markers are increased and have
a prognostic value in clinical renal disease
(Bazzi et al. 2002; Holdt-Lehmann et al.
2000). Post hoc power calculations show that
our study had adequate power to detect an
increase of NAG in the amalgam group of the
size reported by de Burbure et al. (2006). 
Our results, indicating no effects of low-
level mercury from dental amalgam on renal
tubular function in children, do not contra-
dict previous observational studies in adults
showing increased urinary NAG, because the
occupationally exposed subjects in those stud-
ies had U-Hg levels 10–20 times higher
(Ellingsen et al. 2000). However, the afore-
mentioned cross-sectional study of children
by de Burbure et al. (2006) showed an associ-
ation between U-Hg and urinary NAG in
children at very low U-Hg levels, after con-
trolling for BPb and urinary cadmium.
Although a randomized controlled trial is
designed to be unaffected by uncontrolled
confounding factors that often constitute a
problem in observational studies, the present
study did not take into account cadmium and
selenium status, which may influence the
renal tubular toxicity of mercury (de Burbure
et al. 2006; Ellingsen et al. 2000), and should
be included in future studies. We found no
interaction between U-Hg and BPb for the
renal tubular markers. Few studies in children
used γ-GT, but this marker was increased in a
study of infants exposed to phenylmercury
absorbed from diapers (Gotelli et al. 1985).
However, mercury exposure was considerably
higher than in our study.
The only ﬁnding in the present study that
suggested a possible adverse effect of dental
amalgam was the increased occurrence of
MA. The point estimate implied an almost
2-fold risk (prevalence OR), although the
lower bound of the 95% CI was 1.1. This
ﬁnding was strengthened by the fact that 10
of 12 cases with persistent MA were found in
the amalgam group. 
High industrial exposure to inorganic
mercury increases the prevalence of albumin-
uria in adults (Buchet et al. 1980). Moreover,
high exposure may cause membranous
glomerulonephritis with nephrotic syndrome,
in industry (Tubbs et al. 1982) as well as in
the general population (Oliveira et al. 1987).
Within groups with the same exposure, only
some people are affected, and increased
susceptibility may be associated with HLA
phenotype (Enestrom and Hultman 1995).
This is also true for rare mercury hypersensi-
tivity reactions in children (Clarkson and
Magos 2006; Counter and Buchanan 2004;
Weinstein and Bernstein 2003). These effects,
however, have never been shown at low-level
exposure. Animal models indicate that the
mechanisms behind mercury-induced auto-
immunity are complex, and genetic factors,
especially MHC genes, may be important
(Nielsen and Hultman 2002; Pollard et al.
2005; Tubbs et al. 1982). In view of previous
knowledge, our finding of MA in children
treated with dental amalgam may therefore
represent a causal association. If so, our ﬁnd-
ings indicate that children with high BPb may
be more sensitive than others. 
However, chance is clearly an alternative
explanation for a higher occurrence of MA in
the present study. We excluded children with
diabetes or known kidney disease, but tempo-
rary albuminuria is relatively common and
may be caused by strenuous physical exercise,
urinary tract infections, or other conditions
with fever, or it may represent so-called
orthostatic proteinuria (Hogg et al. 2000).
The NHANES study reported the prevalence
of MA in U.S. children and adolescents (6–19
years of age) to be 6.2% in males and 13.4%
in females, when individuals with diabetes or
other relevant diseases had been excluded
(Jones et al. 2002). This is very similar to the
prevalence in the composite group of 9–10%
(boys and girls combined), whereas the preva-
lence in the amalgam group was somewhat
higher. The higher prevalence in girls than in
boys is in accordance with previous knowl-
edge (Jones et al. 2002). The median albumin
levels were in agreement with those reported
for U.S. or European children (Jones et al.
2002; Lehrnbecher et al. 1998). Our samples
were stored frozen for 6 months on average,
which probably led to some decrease of initial
levels. The samples from the NHANES
study, also stored frozen, showed a similar
median albumin level as the NECAT study. 
We searched for two kinds of renal effects:
glomerular and tubular. We tested effects on
mean levels as well as on increased prevalence
in high levels. It is possible that the difference
in one (MA) of these four major outcomes is
just a random finding attributed to multiple
testing. At the same time as the NECAT
study another controlled clinical trial, con-
ducted in Portugal with a nearly identical
design, was published (DeRouen et al. 2006).
No increase in the occurrence of MA has
been found in the Portuguese study (B.
Leroux, personal communication). Unless
there is a genetic difference in susceptibility
between children in the Mediterranean region
and most children in the Northeast United
States, an absence of increased MA in the
Casa Pia study (B. Leroux, personal commu-
nication) makes a causal association in the
present study less likely.
Although we found 10 children in the
amalgam group with MA in both years 3 and
5, we do not know whether these children
will have persistent MA. A more extensive
clinical investigation of these children would
have been valuable. However, the protocol of
this trial did not permit us to investigate fur-
ther. Therefore, the clinical implications are
unclear, should the increase of MA in the
amalgam group reﬂect a causal association. A
reversible MA may be harmless, such as after
many viral infections or strenuous exercise
(Hogg et al. 2000). MA reﬂecting a long-last-
ing effect on glomerular integrity would,
however, be a serious side effect even if only a
small fraction of children were affected. A
study speciﬁcally focused on the possible asso-
ciation between dental amalgam and MA in
children would be desirable. Another ran-
domized controlled study would be optimal
but may require very large groups. An alterna-
tive would be case–referent or case–crossover
studies in surroundings where substantial
fractions of children have and have not had
dental amalgam ﬁllings. 
The U-Hg levels of the children assigned to
the amalgam group were similar to or slightly
higher than those in U.S. adults with a similar
number of dental amalgam surfaces (Dye et al.
2005; Kingman et al. 1998). Given that the
children enrolled had a considerably higher
prevalence of caries than in other U.S. children
of comparable age, the children assigned to the
amalgam group are likely to have experienced
higher exposure to mercury from amalgam than
the average U.S. child. Nevertheless, the ﬁnd-
ings should be relevant for most U.S. children.
A study of 100 low-income, inner-city children
from New York City showed a mean U-Hg of
1.1 µg/L (Ozuah et al. 2003).
Barregard et al.
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recruited children in whom no dental amal-
gam restorations had ever been placed and
assigned them randomly to treatment group.
This experimental design contributed to an
equivalence of treatment groups, at baseline,
on measured and unmeasured factors that
could create confounding or effect modiﬁca-
tion. Second, we recruited children with
many dental caries, providing a setting in
which the study hypotheses could be ade-
quately tested. Third, the design included a
long term follow-up with measurements of
renal markers on several occasions. Fourth,
loss to follow-up was remarkably low for a
U.S. study, with 5-year renal outcome data
for 81% of the children enrolled.
There are, however, also several limita-
tions. First, because the main focus was on
neuropsychological function, the baseline
ascertainment of renal function was limited:
interviews on possible renal disease, a dip-
stick, and measurement of urinary γ-GT.
This screening should, however, detect most
of the children with possible kidney disorders
at baseline. Second, the assessment of one of
the three tubular markers, A1M, was not
optimal because of a high detection limit
(nephelometry) or long storage time (ELISA).
Third, we used spot samples adjusted for cre-
atinine, although 24-hr excretion will have
somewhat lower intraindividual variability.
Fourth, although this trial was adequately
powered to detect a small treatment-group
difference in averages, it has low power to
catch an effect that occurs only in a small sus-
ceptible fraction of children. Fifth, a follow-
up period > 5 years might be needed to
appreciate potential subtle toxic effects of
exposure to mercury from dental amalgam,
such as on renal proximal tubules.
In summary, the present randomized clini-
cal trial showed no effect of amalgam on renal
tubular function. There was, however, an
increased prevalence of MA in children treated
with dental amalgam. This may reﬂect a causal
association or it may be a chance ﬁnding. This
issue should be examined further. 
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